PsyBio Therapeutics Corp (CVE:PSYB) CEO Evan Levine tells Proactive it has initiated process development of its proprietary biosynthetic formulation of norbaeocystin in collaboration with the Advanced Biofuels and Bioproducts Process Development Unit, a scale-up facility managed by Lawrence Berkeley National Laboratory. Levine says norbaeocystin is an analogue of psilocybin. It has commenced Phase I of the formulation process, including analytical chemistry technical transfer to establish detection methods for fermentation products and key feedstocks and metabolites.
PsyBio Therapeutics begins manufacturing its proprietary biosynthetic formulation of norbaeocystin
